Compare
Eton Pharmaceuticals, Inc. vs ADC Therapeutics SA vs Standard Biotools Inc. vs Rockwell Medical, Inc.
| Latest fiscal year | Eton Pharmaceuticals, Inc. ETON | ADC Therapeutics SA ADCT | Standard Biotools Inc. LAB | Rockwell Medical, Inc. RMTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $79.95M | $81.36M | $85.33M | $69.26M |
| Revenue growth (YoY) | +104.9% | +14.9% | -6.2% | -31.8% |
| Gross margin | 53.5% | 92.9% (computed) | 49.9% | 16.9% |
| Operating margin | -1.1% | -149.3% | -129.2% | -6.8% |
| Net margin | -5.8% | -175.3% | -87.8% | -7.7% |
| Net income | -$4.60M | -$142.62M | -$74.90M | -$5.31M |
| EPS (Diluted) | n/a | -$1.12 | -$0.20 | -$0.15 |
| Operating cash flow | $10.52M | -$141.17M | -$74.34M | -$659.0K |
| Free cash flow | $10.19M | -$141.44M | -$82.65M | -$1.20M |
| Cash & equivalents | $25.94M | $261.34M | $120.86M | $10.71M |
| Total assets | $92.11M | $323.15M | $567.75M | $57.15M |
| Total liabilities | $65.96M | $508.98M | $143.46M | $20.16M |
| Shareholders' equity | $26.15M | -$185.83M | $424.29M | $36.98M |
| Return on year-end equity | -17.6% | n/a | -17.7% | -14.4% |
| Shares outstanding | 27.05M | 125.75M | 386.38M | 39.41M |
Revenue, most recent five fiscal years
| Fiscal year | Eton Pharmaceuticals, Inc. | ADC Therapeutics SA | Standard Biotools Inc. | Rockwell Medical, Inc. |
|---|---|---|---|---|
| Latest | $79.95M Ended 2025-12-31 | $81.36M Ended 2025-12-31 | $85.33M Ended 2025-12-31 | $69.26M Ended 2025-12-31 |
| 1 year earlier | $39.01M Ended 2024-12-31 | $70.84M Ended 2024-12-31 | $91.01M Ended 2024-12-31 | $101.49M Ended 2024-12-31 |
| 2 years earlier | $31.64M Ended 2023-12-31 | $69.56M Ended 2023-12-31 | $106.34M Ended 2023-12-31 | $83.61M Ended 2023-12-31 |
| 3 years earlier | $21.25M Ended 2022-12-31 | $209.91M Ended 2022-12-31 | $97.95M Ended 2022-12-31 | $72.81M Ended 2022-12-31 |
| 4 years earlier | $21.83M Ended 2021-12-31 | n/a | $130.58M Ended 2021-12-31 | $61.93M Ended 2021-12-31 |